Arcturus Therapeutics Holdings (ARCT)
(Real Time Quote from BATS)
$27.17 USD
-0.76 (-2.72%)
Updated Apr 24, 2024 12:22 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Arcturus Therapeutics (ARCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$66.00 | $140.00 | $18.00 | 136.31% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Arcturus Therapeutics comes to $66.00. The forecasts range from a low of $18.00 to a high of $140.00. The average price target represents an increase of 136.31% from the last closing price of $27.93.
Analyst Price Targets (7 )
Broker Rating
Arcturus Therapeutics currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy, representing 88.89% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/11/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/8/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
3/8/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
3/1/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
1/10/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
11/28/2023 | Cantor Fitzgerald & Co | Pete Stavropoulos | Not Available | Strong Buy |
10/25/2023 | Robert W. Baird & Co. | Joel L Beatty | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $66.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 78 of 252 |
Current Quarter EPS Est: | -1.17 |